

Founding Members (2/2)



Dr. Peter Greaney

Peter Greaney, PhD. Passionate about innovative drug development driven by data and the smart application of technology for the benefit of patients.

Peter has international experience in building successful biotech companies. He has been responsible for the successful execution of numerous business development deals in his career and has experience in a wide array of deal structures. He is experienced in seeking new business opportunities, leading negotiations and managing research collaborations.

At ADC Therapeutics, Peter was the Head of Corporate Development and played an integral role transforming the company from a private R&D biotech to a NYSE listed public biotech with a commercial therapeutic product.

Prior to ADC Therapeutics, Peter held medical and business positions of increasing responsibility at Celgene in Switzerland and the United States. He held roles in Business Development, Strategy & Operations, Market Research & Business Intelligence, Medical Affairs, and Medical Development. Prior to Celgene, Peter was a Preclinical Senior Scientist at Apoxis, S.A. in Switzerland and an intern scientist at Servier, Paris.

Peter graduated with a Bachelor of Science in Cell Biology from the University of East Anglia and a PhD in Molecular and Cellular Biology from the University of Nottingham (supported by Servier).



Tony Chen

Tony has led Jones Day's China IP team and local counsel in representing clients from a variety of industries in patent invalidation and infringement disputes before China's patent reexamination board and IP courts, including Celgene (pharmaceutical), Cree (semiconductor), SharkNinja (consumer electronics), Lowes (household goods), and Milliken (chemicals). He has guided western companies in navigating China's myriad regulations relating to technology import and export, high and new technology enterprises, cybersecurity, foreign patent filing, and human genetic materials. Tony has worked with Jones Day's litigators in the United States and Europe in representing Chinese companies in litigation involving patent infringement, ITC 337 investigation, trade secret misappropriation, and economic espionage prosecution.

Tony is a leader in public policy projects promoting strong IP protection in China. He is an advisory member of the U.S.-China IP Cooperation Dialogue organized by the U.S. Chamber of Commerce and Renmin University of China. He was an advisor to Shanghai Pudong New Area and Suzhou BioBay on the development of biotechnology industry.



Dr. Ginger Ding

Ginger Ding, PhD, serves as managing director at MSQ Ventures since 2021. At MSQ Ventures, Ginger has been fully responsible for the streamlined execution of transactions by navigating through all the complexity of creative deal structuring and strategic negotiation. Prior to MSQ Ventures, Ginger was the partner at MyBio Capital, serving as cross-border partnering advisor for China based biopharma companies. She is also advisor for Princeton Graduate Consulting Club and Texas Medical Center Consulting Club. Ginger holds an PhD in biochemistry,, and obtained advanced training at UC San Diego and MD Anderson Cancer Center. In her academia life, Ginger has a 10-year track record in biomedical research: Ginger was an awardee of Susan G. Komen grant in support of her pre-clinical studies focusing on brain metastasis, and co-developed 2 RO1 funded by NIH. Ginger is also a popular science writer, specializing in oncology sector.



Echo Hindle-Yang

Echo is on a mission to make technology accessible by bridging the gap between different regions. Echo is unique in that she has 20 years of experience in cross-border transactions for fortune global companies, such as IBM, Lenovo and J&J. In recent years, making the global movement of the healthcare industry has been Echo's focus. She has been advising hundreds of western pharmaceutical and medical devices companies on advancing their success in China including subsidiaries of Novartis, Daichi, and other top global healthcare companies.

Echo holds an MBA from Duke University and the FINRA Series 7, 63 and 79 securities licenses.

Currently Echo is serving on DukeNY Board.